Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyLothar Bergmann, Michael Staehler, Ulrich Kube et al.|BMC Cancer|2015Cited by 23
Rapid and Sustained Influence of Intravenous Zoledronic Acid on Course of Pain and Analgesics Consumption in Patients with Cancer with Bone Metastases: A Multicenter Open-Label Study Over 1 YearAlbrecht Kretzschmar, Gerhard Ehninger, Thomas Wiege et al.|Supportive Cancer Therapy|2007Cited by 19
Everolimus in Metastatic Renal Cell Carcinoma after Failure of Initial Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor (VEGFr-TKI) Therapy: Results of an Interim Analysis of a Non-Interventional StudyLothar Bergmann, Christian Doehn, Peter J. Goebell et al.|Oncology Research and Treatment|2013Cited by 15
Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.Peter J. Goebell, Lothar Bergmann, Ulrich Kube et al.|Journal of Clinical Oncology|2014Cited by 5
Zoledronic acid (Z) as palliative treatment in cancer patients with bone metastases: Interim results of a prospective, open-label trialAlbrecht Kretzschmar, Gerhard Ehninger, Thomas Wiegel et al.|Journal of Clinical Oncology|2004Cited by 2